A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

Mohamad Bassam Sonbol, Talal Hilal, Amylou Dueck, Allison C. Rosenthal, Christopher R. Conley, Heidi E. Kosiorek, Brenda F. Ginos, Katherine M. Gano, Craig S. Nichols, Jose F. Leis, Patrick Bruce Johnston, Thomas Matthew Habermann, Donald W Northfelt, Peter Leif Bergsagel, David J. Inwards, Thomas Elmer Witzig, Stephen Maxted Ansell, Craig B. Reeder

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51–80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62%), with 4 (19%) CR. The ORR was 7/8 (88%) in FL and was 4/5 (80%) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jan 11 2018

Fingerprint

Mantle-Cell Lymphoma
Cyclophosphamide
Dexamethasone
Safety
Peripheral Nervous System Diseases
Histology
Bortezomib
Rituximab
Therapeutics

Keywords

  • CyBorD
  • follicular lymphoma
  • mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • phase II trials

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. / Sonbol, Mohamad Bassam; Hilal, Talal; Dueck, Amylou; Rosenthal, Allison C.; Conley, Christopher R.; Kosiorek, Heidi E.; Ginos, Brenda F.; Gano, Katherine M.; Nichols, Craig S.; Leis, Jose F.; Johnston, Patrick Bruce; Habermann, Thomas Matthew; Northfelt, Donald W; Bergsagel, Peter Leif; Inwards, David J.; Witzig, Thomas Elmer; Ansell, Stephen Maxted; Reeder, Craig B.

In: Leukemia and Lymphoma, 11.01.2018, p. 1-7.

Research output: Contribution to journalArticle

Sonbol, Mohamad Bassam ; Hilal, Talal ; Dueck, Amylou ; Rosenthal, Allison C. ; Conley, Christopher R. ; Kosiorek, Heidi E. ; Ginos, Brenda F. ; Gano, Katherine M. ; Nichols, Craig S. ; Leis, Jose F. ; Johnston, Patrick Bruce ; Habermann, Thomas Matthew ; Northfelt, Donald W ; Bergsagel, Peter Leif ; Inwards, David J. ; Witzig, Thomas Elmer ; Ansell, Stephen Maxted ; Reeder, Craig B. / A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. In: Leukemia and Lymphoma. 2018 ; pp. 1-7.
@article{2b4c62722e4f4639ac559629e366b94e,
title = "A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma",
abstract = "In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51–80) and 17 (81{\%}) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62{\%}), with 4 (19{\%}) CR. The ORR was 7/8 (88{\%}) in FL and was 4/5 (80{\%}) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile.",
keywords = "CyBorD, follicular lymphoma, mantle cell lymphoma, Non-Hodgkin lymphoma, phase II trials",
author = "Sonbol, {Mohamad Bassam} and Talal Hilal and Amylou Dueck and Rosenthal, {Allison C.} and Conley, {Christopher R.} and Kosiorek, {Heidi E.} and Ginos, {Brenda F.} and Gano, {Katherine M.} and Nichols, {Craig S.} and Leis, {Jose F.} and Johnston, {Patrick Bruce} and Habermann, {Thomas Matthew} and Northfelt, {Donald W} and Bergsagel, {Peter Leif} and Inwards, {David J.} and Witzig, {Thomas Elmer} and Ansell, {Stephen Maxted} and Reeder, {Craig B.}",
year = "2018",
month = "1",
day = "11",
doi = "10.1080/10428194.2017.1416368",
language = "English (US)",
pages = "1--7",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

AU - Sonbol, Mohamad Bassam

AU - Hilal, Talal

AU - Dueck, Amylou

AU - Rosenthal, Allison C.

AU - Conley, Christopher R.

AU - Kosiorek, Heidi E.

AU - Ginos, Brenda F.

AU - Gano, Katherine M.

AU - Nichols, Craig S.

AU - Leis, Jose F.

AU - Johnston, Patrick Bruce

AU - Habermann, Thomas Matthew

AU - Northfelt, Donald W

AU - Bergsagel, Peter Leif

AU - Inwards, David J.

AU - Witzig, Thomas Elmer

AU - Ansell, Stephen Maxted

AU - Reeder, Craig B.

PY - 2018/1/11

Y1 - 2018/1/11

N2 - In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51–80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62%), with 4 (19%) CR. The ORR was 7/8 (88%) in FL and was 4/5 (80%) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile.

AB - In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51–80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62%), with 4 (19%) CR. The ORR was 7/8 (88%) in FL and was 4/5 (80%) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile.

KW - CyBorD

KW - follicular lymphoma

KW - mantle cell lymphoma

KW - Non-Hodgkin lymphoma

KW - phase II trials

UR - http://www.scopus.com/inward/record.url?scp=85041124984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041124984&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1416368

DO - 10.1080/10428194.2017.1416368

M3 - Article

C2 - 29320913

AN - SCOPUS:85041124984

SP - 1

EP - 7

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -